Feed CPRX
CP

Catalyst Pharmaceuticals

CPRX · NASDAQ

$31.49 -0.02% (-$0.01)
Market Cap $3.85B
P/E Ratio 17.42x
Div. Yield -
ROE 23.65%

Bulios Fair Price

$41.2

30.8% upside

Preț actual

$31.49

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile CPRX sunt în prezent subevaluate față de prețul lor de piață. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Moderate
4/9
Valuation
66 /100
Fair
P/E 17.42x
PEG 0.58x
EV/EBITDA 11.12x
Growth
100 /100
Growing
EPS growth 30.84%
Book val. growth 47.00%
Rev. growth 40.10%
Profitability
100 /100
Strong
Gross margin 122.04%
FCF margin 34.86%
Net margin 37.08%
Quality
91 /100
Excellent
ROIC 19.67%
Asset turnover 0.52x
ROE 23.65%
Debt
100 /100
Low
Debt/Equity 0.00x
Net debt/EBITDA -2.70x
Current ratio 7.10x
Stability
50 /100
Moderate
Beta 0.74x
Profitable years 6
Rev. volatility 37.15%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre CPRX
Online

Despre companie

Catalyst Pharmaceuticals, Inc. (CPRX) is an American biopharmaceutical company specializing in research, development, and commercialization of drugs for rare neurological disorders. With activities in biotechnology and pharmacology, Catalyst Pharmaceuticals is a key player in the world of innovative treatment approaches. Their research focuses on discovering new treatment options and therapies for patients with neurological disorders, such as Lambert-Eaton myasthenic syndrome (LEMS). The company aims to provide modern treatment solutions and improve the quality of life for patients with rare diseases. Catalyst Pharmaceuticals is characterized by expertise in pharmacology and neurology. Catalyst Pharmaceuticals, Inc. (CPRX) shares could be suitable for investors looking for an investment opportunity in the biopharmaceutical sector with a company that specializes in innovative treatment approaches and therapies for patients with rare neurological disorders.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Richard John Daly

Employees

182

Headquarters

Coral Gables

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.